Wilms Tumor Biology and Treatment Strategies

Wilms tumour is the most common paediatric renal malignancy, arising from disrupted nephrogenesis during fetal kidney development. Its pathobiology reflects a convergence of genetic mutations, epigenetic alterations and aberrant developmental signalling. Key driver genes include WT1, WTX and CTNNB1, while imprinting defects at 11p15.5 and gain of chromosome 1q represent recurrent molecular events. Histologically, tumours may exhibit blastemal, epithelial or stromal differentiation, with anaplastic change denoting high risk. Standard management integrates preoperative or immediate nephrectomy, risk-adapted chemotherapy regimens (vincristine, actinomycin D and, in selected cases, doxorubicin) and tailored radiotherapy. International trials have refined protocols to optimise survival—currently exceeding 90% in many settings—while endeavouring to reduce late effects of treatment. Contemporary research focuses on refining molecular risk stratification, identifying novel therapeutic targets, preserving renal function through nephron-sparing techniques and addressing global outcome disparities. Advances in imaging, surgical planning and integration of biology-driven biomarkers promise to personalise therapy further and improve both short-term and long-term outcomes for children worldwide.

Research from Nature Portfolio

Recent studies have elucidated the genetic and epigenetic landscape of bilateral Wilms tumour predisposition by comprehensive sequencing and methylation profiling. This work has revealed that germline variants in WT1, TRIM28 and other predisposition genes coexist with post-zygotic hypermethylation at the H19/ICR1 imprinting centre on 11p15.5. Such dual mechanisms account for the majority of synchronous bilateral cases and inform diagnostic strategies requiring multi-tissue analysis. In a broader synthesis of current understanding, a recent disease primer has highlighted the multiple nephrogenic pathways co-opted in tumourigenesis. This review emphasises the interplay of developmental transcription factors, cell-cycle regulators and DNA-damage response pathways. It also underscores the slow incorporation of targeted agents into clinical protocols, the necessity of international collaboration to address survival disparities and the potential of advanced imaging and organoid models to accelerate new treatment development.

Wilms Tumor Biology and Treatment Strategies publication trend

The graph below shows the total number of articles in wilms tumor biology and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Nephrogenesis: The process of kidney development from metanephric mesenchyme to mature nephrons.

Imprinting: Parent-of-origin specific gene expression regulated by DNA methylation at imprinting control regions such as H19/ICR1.

Epigenetic hypermethylation: Excessive addition of methyl groups to DNA, often silencing gene expression without altering the DNA sequence.

Loss of heterozygosity (LOH): Genetic event in which one allele of a gene is lost, unmasking mutations on the remaining allele.

Cancer stem cell: A subpopulation of tumour cells capable of self-renewal and driving tumour initiation and recurrence.

Chromosome 1q gain: Copy number increase of the long arm of chromosome 1, associated with adverse prognosis in Wilms tumour.

References

1. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children’s Oncology Group AREN18B5-Q. Nature Communications (2023).
2. Wilms tumour. Nature Reviews Disease Primers (2021).
3. Identification and Characterization of the Wilms Tumor Cancer Stem Cell. Advanced Science (2023).
4. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. Journal of Clinical Oncology (2016).
5. Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. The Lancet (2015).